Genentech is pulling Raptiva (efalizumab) from the market due to the risk of an opportunistic brain infection called PML
May 2009
Genentech is pulling Raptiva (efalizumab) from the market due to the risk of an opportunistic brain infection called PML.
PML (progressive multifocal leukoencephalopathy) is caused by a virus that attacks the brain when the immune system is severely weakened...usually due to AIDS, immunosuppressant therapy, etc.
Several long-term users of Raptiva have developed progressive multifocal leukoencephalopathy...most have died.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote